drugset
drugset / Trial / NCT00113295

Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder

NCT00113295 ↗

Phase 4 Completed 50 enrolled Massachusetts General Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to examine the safety and efficacy of quetiapine for generalized anxiety disorder patients who remain symptomatic despite treatment with paroxetine CR.

Timeline

Start
2004-02
Primary completion
2007-02
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 200 mg —
Background Paroxetine Small molecule 62.5 mg —

Indications

generalized anxiety disorder